Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.03 USD | +1.77% | +6.05% | +9.02% |
05-09 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-08 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.02% | 19.43M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise